(Reuters) – U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial.
The drug, neflamapimod, did not achieve the trial’s main goal of significantly reducing symptoms of dementia, but the company said it believed the treatment had potential and would investigate the reasons for the results.
CervoMed was testing neflamapimod as a treatment for a form of dementia caused by the accumulation of protein deposits called Lewy bodies in the brain’s nerve cells.
Shares of the company were halted in premarket hours.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil D’Silva and Devika Syamnath)
Comments